Inhibitors of class I HDACs and of FLT3 combine synergistically against leukemia cells with mutant FLT3

Acute myeloid leukemia (AML) with mutations in the FMS-like tyrosine kinase (FLT3) is a clinically unresolved problem. AML cells frequently have a dysregulated expression and activity of epigenetic modulators of the histone deacetylase (HDAC) family. Therefore, we tested whether a combined inhibitio...

Descripción completa

Detalles Bibliográficos
Autores principales: Wachholz, Vanessa, Mustafa, Al-Hassan M., Zeyn, Yanira, Henninger, Sven J., Beyer, Mandy, Dzulko, Melanie, Piée-Staffa, Andrea, Brachetti, Christina, Haehnel, Patricia S., Sellmer, Andreas, Mahboobi, Siavosh, Kindler, Thomas, Brenner, Walburgis, Nikolova, Teodora, Krämer, Oliver H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Molecular Toxicology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8748367/
https://www.ncbi.nlm.nih.gov/pubmed/34665271
http://dx.doi.org/10.1007/s00204-021-03174-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8748367/
https://www.ncbi.nlm.nih.gov/pubmed/34665271
http://dx.doi.org/10.1007/s00204-021-03174-1

Ejemplares similares